BLI 1401

Drug Profile

BLI 1401

Alternative Names: BLEX-404; BLI-1401; BLI-1401-2

Latest Information Update: 04 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioLite Inc
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Breast cancer; Myelodysplastic syndromes
  • Preclinical Chronic lymphocytic leukaemia

Most Recent Events

  • 09 Oct 2017 Rgene Corporation plans a phase I/II trial for Pancreatic cancer (Late-stage disease, Metastatic disease, Inoperable/unrescetable) (NCT03301805)
  • 24 Oct 2016 BioLite plans a phase II trial for Myelodysplastic syndromes and Chronic myelomonocytic leukaemia (First-line therapy, Combination therapy) in USA (PO, Liquid) (NCT02944955)
  • 04 Oct 2016 Preclinical trials in Chronic lymphocytic leukaemia in Taiwan (PO) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top